AL8DB
Alderan Resources Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-3.33%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Alderan Resources Limited
📈 Performance
Price History
-85.00%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.03
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AL8DB
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in AL8DB
N/A
AL8DB investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in AL8DB also invest in...
Want more shares? Try these...
Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. The firm is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The firm's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The firm is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.
🙌 Performance (5Yr p.a)
44.08%
📊 Share price
$0.19 AUD
📦 LOGISTICS
📈 HIGH PRICE GROWTH
AML3D Ltd. engages in the provision of 3D printing services and machinery. The company is disrupting metal part supply chains using the Company’s patented wire additive manufacturing (WAM) process. WAM combines state-of-the-art welding science, robotics automation, materials engineering, and proprietary software to lead metal additive manufacturing globally. The company is the original equipment manufacturer (OEM) of the ARCEMY industrial metal 3D printing systems. ARCEMY uses WAM to provide advanced, automated, point-of-need 3D manufacturing solutions that are efficient, cost-effective and have ESG outcomes compared to traditional casting, forging and billet machining processes. ARCEMY is the Internet of Things (IoT) and Industry 4.0 enabled to allow manufacturers across aerospace, defense, maritime, manufacturing, mining and oil & gas to become globally competitive. The company also provides metal 3D printing design engineering services, software licensing, technical support, consumable sales and contract manufacturing services.
📊 Share price
$0.21 AUD
🚜 MACHINERY
